MONDAY, AUGUST 17

Keynote Address
James P. Allison, University of Texas MD Anderson Cancer Center, USA

Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms

Mechanisms of Action I

*Ira Mellman*, Genentech, Inc., USA
Mechanistic Basis of Cancer Immunotherapy

*Kelli Connolly*, Yale University, USA
Short Talk: Tumor-Draining Lymph Nodes Contain an Untapped Reservoir of Stem-Like CD8 T Cells

*AHyun Choi*, Novartis Institutes for BioMedical Research, USA
Short Talk: Loss of EMC Inhibits Tumor Growth through Enhanced Adaptive Immune Response

Mechanisms of Action II

*Jane Oliaro*, Peter MacCallum Cancer Centre, Australia
Identifying New Targets for Cancer Immunotherapy

*Vandana Kalia*, University of Washington and Seattle Children’s Research Institute, USA
Short Talk: PD-1 Signals Are Critical for Maintenance of CD8 T Cell Memory

Mechanisms of Response I

*Siwen Hu-Lieskovan*, Huntsman Cancer Institute, USA
Clinical Testing Strategies against Heterogeneous Mechanisms of Immune Resistance

*Antoni Ribas*, University of California, Los Angeles, USA
Mechanisms of Primary and Acquired Resistance to PD-1 Blockade Therapy

*Chang Liu*, University of Pittsburgh, USA
Short Talk: Neuropilin-1 Is a T Cell Memory Checkpoint Limiting Long-Term Anti-Tumor Immunity

Mechanisms of Response II

*Padmanee Sharma*, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy

*Yuxuan Miao*, Rockefeller University, USA
Short Talk: Adaptive Immune Resistance Emerges From Tumor-Initiating Stem Cells

Shira Tabachnick-Cherny, University of Washington, USA
Short Talk: Characterization of Myeloid Cells Subsets in the Tumor Microenvironment of Merkel Cell Carcinoma

Zoila Areli Lopez Bujanda, NYU, USA
Short Talk: ADT-Mediated Intra-Tumoral Myeloid Infiltration Promotes Resistance to Immune Checkpoint Blockade in Prostate Cancer

Poster Session

TUESDAY, AUGUST 18

Therapeutic Play I

*Yvonne Y. Chen*, University of California, Los Angeles, USA
Engineering Next-Generation CAR-T Cell Therapy for Cancer

*Juan C. Jaen*, Arcus Biosciences, Inc., USA
Clinical Applications of Adenosine Pathway Inhibitors

*Coralie Backlund*, Massachusetts Institute of Technology, USA
Short Talk: Cell Penetrating Peptides Improve T Cell Response to Neoantigen Peptide Vaccines

*Majja Hollmén*, University of Turku, Finland
Short Talk: Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumours

*Yingxiao Wang*, University of California, San Diego, USA
Short Talk: Engineering Remotely Controllable CAR T Cells for Cancer Immunotherapy

Therapeutic Play II

*Evan Scott*, Northwestern University, USA
Engineered Nanobiomaterials for Cancer Immunotherapy

*E. John Wherry*, University of Pennsylvania, USA
Epigenetic Features of Exhausted Antitumor T Cells

*Buvana Ravishankar*, Rapt Therapeutics, Inc., USA
Short Talk: Targeting the Stress Response Kinase GCN2 Potentiates Anti-Tumor Immune Response

*Anthony K. Park*, City of Hope, USA
Short Talk: Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors

*Patrick A. Ott*, Dana-Farber Cancer Institute, USA
Short Talk: Personal Neoantigen Vaccines Induce Long-term Immune Responses in Patients with High Risk Melanoma

Meet-the-Editors Roundtable

Alessandra Fornarelli, Frontiers, Switzerland
Paloma Portela Torres, SAGE Publications Ltd, UK
Lise Roth, European Molecular Biology Organization, Germany

Genomics of Cancer I

*Priti Hegde*, Foundation Medicine, USA
Pan-Cancer Analysis of Allele-Specific HLA-I Loss Suggests Widespread Occurrence across a Diverse Range of Tumor Types

Eliezer M. Van Allen, Dana-Farber Cancer Institute, USA
Tumor Genomics and Selective Response to Cancer Immunotherapy
**Nadine A. Defranoux**, Parker Institute for Cancer Immunotherapy, USA
Short Talk: Strategies to Improve the Sensitivity and Ranking Ability of Neoantigen Prediction Methods: Report on the Results of the Tumor nEoantigen SeLection Alliance (TESLA)

**Gloria Bora Kim**, University of Pennsylvania, USA
Short Talk: Splice Variants as Neoantigens for Cancer Immunotherapy

**Elaine R. Mardis**, Nationwide Children's Hospital, USA
*Immunogenomics and the TME in Pediatric CNS Cancers*

**Thomas D. Wu**, Genentech, Inc., USA
Short Talk: Peripheral T Cell Expansion Predicts Tumor Infiltration and Clinical Response to Cancer Immunotherapy

**Debattama Sen**, Massachusetts General Hospital, USA
Short Talk: Disrupting Enhancers within the Core Epigenetic Program of Exhaustion Improves CD8+ T Cell Responses and Enhances Tumor Control

**WEDNESDAY, AUGUST 19**

**Single Cell I**

**James R. Heath**, Institute for Systems Biology, USA
*Single Cell Approaches to Analyzing Antitumor Responses*

**Ansuman Satpathy**, Stanford University School of Medicine, USA
Single-Cell Genomics in Cancer Immunotherapy

**Christine Carine Moussion**, Genentech, Inc., USA
Short Talk: Local Heterogeneity of Response to CIT: Learning from the STAMP Live Imaging Model

**James C. Lee**, University of California, San Francisco, USA
Short Talk: Liver Metastasis Mediated Control of Systemic Tumor-Specific Immunity and Response to Checkpoint Immunotherapy

**Single Cell II**

**Sohail F. Tavazoie**, Rockefeller University, USA
Depleting Myeloid-Suppressive Cells for Cancer Immunotherapy

**Theodore Roth**, University of California, San Francisco, USA
Short Talk: Parallel Engineering of Immune Cell Genomes by Pooled Knockin Targeting

**Amanda Oliver**, Peter MacCallum Cancer Centre, Australia
Short Talk: Tissue-Specific Tumour Microenvironments Influence Responses to Immunotherapy